Ajude o World Market Atlas a crescer
Ao encomendar uma avaliação de empresa, também apoia o desenvolvimento do projeto.
Apoie o projeto
Ajude a desenvolver o World Market Atlas, um projeto independente para investidores individuais. O seu apoio permite-nos produzir análises e melhorar as ferramentas.
Comentários de mercado
A minha perspectiva sobre os mercados, a economia e os acontecimentos que interessam aos investidores.
Czechoslovak Group: valuing CSG after its margin guidance cut
EN O texto do artigo está disponível em inglês; o título está traduzido.
EN Information cutoff: 11 November 2026. Balance sheet and DCF anchor: 30 September 2026. Nine-month results are unaudited. Reported data, management guidance and author assumptions are distinguished. Values in EUR unless stated otherwise.
Czechoslovak Group has an appealing industrial opportunity, but its value depends on cash rather than the size of its order book alone. Our educational DCF indicates approximately EUR 16.4 per share in the base case, within a EUR 5.8–29.5 scenario range. It incorporates the nine-month update released on 11 November. This is a conditional valuation anchored to the 30 September balance sheet, not a current price target.
1. What does a CSG shareholder own?
CSG N.V. is the Amsterdam-listed holding company of Czechoslovak Group. Ticker: CSG, ISIN: NL0015073TS8, trading currency: EUR. The business spans ammunition, military vehicles and defence electronics, grouped into Defence Systems and Ammo+. Security information · Business presentation
Trading began on 23 January 2026 at EUR 25, with one billion shares and a EUR 25bn market capitalisation. The primary issue comprised 30m shares raising EUR 750m gross; existing-share sales benefited the selling shareholder rather than the group. IPO announcement
In 2025, revenue reached EUR 6.741bn and adjusted EBIT EUR 1.626bn. Acquisitions, including the integration of The Kinetic Group, expanded the business: reported revenue growth is not synonymous with organic growth. IR historical figures · 2025 results
2. The 11 November update: lower margins change the valuation
*EBIT comparisons include a 2025 PPA adjustment. These are alternative performance measures and the update is unaudited. Statement, pp. 3–5 and 11–12
Management maintained 2026 revenue guidance at EUR 7.4–7.6bn, but reduced the EBIT margin from 24–25% to approximately 21%. At EUR 7.5bn sales, that implies EUR 1.575bn EBIT, EUR 262.5m below the previous midpoint. This is our calculation from guidance, not an additional company forecast. Management attributes the margin reduction to selling standard-range ammunition inventory at lower prices and a growing Land Systems contribution, where profitability is still developing as programmes ramp up.
3. Why have profits not yet converted into cash?
Net working capital was EUR 2.949bn at 30 September. Inventory and receivables tie up capital before delivery and customer payment. CSG now expects year-end 2026 NWC below 35% of revenue, against the previous 20%; capex guidance remains approximately 8.5% of revenue. Presentation, pp. 9 and 20
A valuation must ask two separate questions: what a contract earns and how much cash must be committed before completion. Slower inventory release reduces our modelled FCFF even without a decline in accounting profit. We do not confuse the company’s after-interest FCF with the FCFF used in our DCF.
4. The EUR 18bn backlog needs to be unpacked
CSG reports EUR 7bn fixed, EUR 8bn frame and EUR 3bn soft backlog, alongside EUR 29bn of pipeline under negotiation. Frameworks require execution terms to be agreed; soft backlog is not fully finalised. We do not treat the combined EUR 47bn as unconditional contracted sales. Portfolio table and definitions, pp. 5–6
Author interpretation: demand visibility helps factory planning, but a revenue forecast still requires judgements about delivery dates, pricing and execution. A euro of pipeline does not carry the same certainty as an effective contract.
5. How did we build the DCF?
Author assumptions. We value 100% of operating activity using FCFF: EBIT × (1 − tax) + depreciation − capex − change in NWC. The balance-sheet anchor is 30 September 2026. Q4 is discounted for 0.25 years, followed by 2027–2031 cash flows at 1.25–5.25 years. The balance sheet has not been rolled forward to 11 November. The output is not a 12-month price target.
Our 2026 inputs are EUR 7.5bn revenue, 21% EBIT margin, a 23% model tax rate and NWC at 34% of sales. Q4 depreciation is EUR 51m and capex EUR 383.5m, deducting EUR 254m nine-month capex from modelled full-year investment. NWC releases EUR 399m. The result is EUR 430.7m Q4 FCFF. These are our calculations; achieving such a strong year-end remains a risk.
The 10.5% WACC is an author-selected required return, not an observed beta or measured CAPM output. An illustrative build is 80% equity at 12% cost and 20% debt at 6% before 23% tax: 10.52%, rounded to 10.5%. Every component is an assumption.
Perpetual growth is 2.5%, with terminal ROIC of 15%. Terminal reinvestment is explicit: terminal FCFF = NOPAT × (1 − g / ROIC). Growth beyond 2031 therefore requires capital. Revenue is forecast as an aggregate proxy; contract-level timing and independently verified price/volume schedules are unavailable.
6. Base forecast and the bridge to equity
All forecasts below are author assumptions, in EUR bn. Revenue growth fades from 14% in 2027 to 6% in 2031. The EBIT margin reaches 25% before normalising to 24%, below management’s reaffirmed 26–28% medium-term ambition. Management targets, p. 20
From 2027, depreciation is 2.5% of revenue; capex declines from 6.5% to 5%, while NWC falls from 28% to 22%. Model capex covers economic maintenance and growth investment, including replacement of leased assets; leases are treated as financing in net debt. We do not blindly copy CSG’s capex measure, which also includes certain acquisitions.
We deduct the full EUR 4.320bn reported net debt rather than EUR 2.889bn adjusted debt. We separately add an assumed EUR 731m value for JV/stakes and 80% of EUR 700m supplier loans. These are approximate asset values, not cash, and are not counted again in FCFF. Debt reconciliation, pp. 19 and 29
We provisionally value minorities at EUR 1bn: their nine-month earnings were EUR 77m, approximately EUR 103m on a simple annualised basis, at an assumed multiple of roughly 10×. This is a proxy, not an independent subsidiary appraisal. Increasing this deduction by EUR 500m reduces per-share value by EUR 0.50. Minority earnings, p. 23
We treat the October purchase of 9.5% of MDA Space as an additional investment with zero incremental net asset value at acquisition: asset value equals purchase cash outlay, offset by an equal cash or debt adjustment. No additional synergy premium is included; the 30 September balance-sheet anchor is retained. Subsequent valuation changes, financing and derivatives require separate revaluation. MDA announcement
7. Three scenarios and sensitivity
All scenarios retain the same Q4 stub and balance-sheet bridge. The downside case weakens performance from 2027; it is not the worst possible outcome. No arbitrary scenario probabilities are assigned.
Sensitivity of the base operating path, EUR per share:
69.1% of EV comes from terminal value. Profitability beyond 2031 therefore matters heavily; cents are shown for arithmetic transparency rather than economic precision.
8. What would make the valuation hold up?
The EUR 25 IPO price is a historical benchmark. The absence of a verified, synchronised EUR quote on the publication date limits comparison with the current market. Keeping other base inputs constant, justifying it would require a 2031 and terminal EBIT margin of approximately 37.5%, against 24% in our base case. This single-variable mathematical backsolve does not reveal market expectations.
The warning from trading is visible: the official Prague exchange page showed CZK 285, down 14.87%, at 09:50:30 on 11 November in delayed data. This is a dated local intraday observation, not a closing price or Amsterdam EUR quote; we do not derive an “upside” percentage from it. Prague Stock Exchange
CSG’s company-compiled consensus, published on 4 November, expected EUR 1.859bn adjusted EBIT in 2026. It predates today’s guidance cut; our model does not treat it as a refreshed post-release forecast. IR consensus, 4 November 2026
Author assessment: wait for evidence of cash conversion. Base value depends on revenue growth, recovering margins and lower working-capital intensity. No stock-market multiple expansion is required, but effective industrial execution is.
This is a preliminary, screen-grade scenario analysis. It lacks a full contract schedule, separate appraisals of every subsidiary, current derivative valuations and an empirically measured beta. Educational material; not an investment recommendation.
Marcus Lepidus · 11 November 2026
As publicações refletem as opiniões pessoais do autor à data da publicação. Não são recomendações de investimento.